Shadow AI Clinical Research: Blinded Data and Trial Records in Prompts

A clinical research associate copies a monitoring finding into a personal AI assistant to make it concise. The paragraph includes a coded participant ID and an investigator comment. It also reveals the assigned treatment. The trial system still shows a padlock beside the blinded field, but the outgoing HTTP request carries none of that access context. Shadow AI clinical research begins in that split.

The governance question is which uses a sponsor should approve and validate. This article owns the escaped request: participant or trial material sent through an unregistered account or endpoint before the sponsor's approved controls can act. An unapproved purpose creates the same escape.

TL;DR

• Trial content can lose subject, study, and blinding labels when copied into an unauthorized model prompt.
• Sponsor approval must bind the requester and purpose to the trial, content class, model route, and current policy.
• Decision records should connect the blocked or allowed request to the study system without duplicating the full regulated record.
• DeepInspect governs authenticated HTTP LLM traffic routed through it. Local analysis, opaque vendor AI, file transfer, and non-HTTP paths need adjacent controls.

Shadow AI clinical research strips trial labels

Clinical systems carry structured context. An electronic data-capture record knows the study and site. The randomization system knows treatment access. A safety platform knows the case status and reporting workflow. Paste the visible text into a chat box and those controls stay behind.

The model receives the substance. That split matters. A coded subject identifier can still be linkable within the study, while protocol deviations reveal site performance and interim tables may expose a treatment signal before the approved analysis has reached its authorized readers. A draft investigator brochure may contain unreleased safety information.

The healthcare shadow AI article covers the wider PHI and BAA problem. Clinical research adds trial authorization and blinding state to the request path. I would deny any routed prompt containing study data when the application fails to provide a stable trial identifier. A generic research purpose is too vague for material that can alter study conduct.

Blinding is an authorization attribute at request time

A user may be permitted to view a source record and still lack authority to send its content to a model. That is the post-authentication gap in a trial setting. The policy point needs the natural person or agent and trial role. It also needs blinding status and intended task.

A blinded monitor can use an approved assistant on a route restricted to ordinary monitoring text. Treatment assignments and unblinded analysis terms should trigger another policy. The request may be denied outright or directed to a separately approved endpoint with a narrower role. A short output cannot repair an unauthorized disclosure that already reached the wrong provider.

The physical clue is small: one open padlock icon beside a treatment column. Request evidence should preserve the supplied blinding context and detected content class, followed by destination and outcome. It should avoid copying the entire subject narrative unless the sponsor's retention design requires that duplicate.

Electronic-record guidance reaches the model-assisted step

FDA's 2024 final guidance notice on electronic systems in clinical investigations addresses sponsors and investigators, plus IRBs and CROs. Its stated goals include data-integrity and security controls, audit trails, record protection, risk-based validation, and service-provider recommendations.

An unauthorized model route undermines that chain because the sponsor lacks a defined service-provider record and controlled electronic path. The official trial system may retain only the edited paragraph pasted back by the user. It cannot show the source text sent out, the model endpoint, or the policy that governed transmission.

For approved traffic, the AI data lineage guide explains the source-to-output connection. Shadow AI demands evidence one step earlier. Record the policy decision before the request leaves. Link it to the trial system through a controlled event ID rather than treating a chat transcript as the clinical record.

Sponsor and CRO boundaries create route ambiguity

A sponsor may approve one model endpoint for medical writing while a CRO uses another service for monitoring reports. A site coordinator can open a consumer assistant outside both routes. The same study therefore has several technical owners.

FDA's 2025 notice adopting ICH E6(R3) Good Clinical Practice emphasizes proportionality and risks to participants, along with reliable results and clearer responsibilities for delegated trial conduct. The guidance is nonbinding FDA thinking unless a cited requirement applies. Its responsibility model is still useful for route ownership.

The sponsor-CRO agreement should name customer-controlled model calls and embedded vendor inference. It should define event access and change notice, plus incident handling and retention. At runtime, an authenticated request should carry the delegated organization and user role. Contract language supplies the relationship. Per-request evidence shows which route actually ran.

Discovery and enforcement cover different trial paths

Endpoint and browser telemetry can identify consumer AI use on managed research devices. Egress controls can restrict unknown model destinations. SaaS review can expose AI features added to an electronic trial master file or safety platform. These controls find paths that bypass the approved request layer.

Authenticated HTTP calls from sponsor or CRO applications can be routed through inline policy. Local statistical work and offline models sit outside that boundary. File uploads through an unmanaged browser can bypass it as well. Vendor-managed inference may remain entirely inside the provider environment. Secure file transfer and data-room controls cover other protocols.

AI policy enforcement at the HTTP layer describes the managed route. It does not validate an endpoint analysis or protect a randomization database by itself. Statistical validation and source-data review remain in qualified systems. Safety assessment and reporting stay with the assigned medical functions.

DeepInspect

DeepInspect sits inline between authenticated clinical-research applications or agents and HTTP-based LLM endpoints. The calling application supplies identity and trial context. DeepInspect classifies the routed prompt and evaluates role, blinding state, destination, and versioned policy before permitting, redacting, or blocking transmission.

Each decision creates an identity-bound record for that managed HTTP path. Local analyses and consumer-browser bypass remain outside it. Opaque vendor inference and non-HTTP data movement sit outside it too. DeepInspect leaves trial design and informed consent with their owners, along with statistical validation and medical judgment.

Book a technical deep dive at deepinspect.ai.